Heidrun Gevensleben

Pathology of Breast and Ovarian Cancers among <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers: Results from the Consortium of Investigators of Modifiers of <i>BRCA1</i> / <i>2</i> (CIMBA)

Nasim Mavaddat, Daniel Barrowdale, Irene L. Andrulis et al. · Cancer Epidemiology Biomarkers & Prevention · 2012 · 649 citations · Full text

The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial

Shahneen Sandhu, William R. Schelman, George Wilding et al. · The Lancet Oncology · 2013 · 551 citations

Sporadic Cancer, Medicine, Brca Mutation Carriers +7

Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial

Nicholas C. Turner, Belinda Kingston, Lucy Kilburn et al. · The Lancet Oncology · 2020 · 334 citations · Full text

Forced Mitotic Entry of S-Phase Cells as a Therapeutic Strategy Induced by Inhibition of WEE1

Marieke Aarts, Rachel Sharpe, Isaac García-Murillas et al. · Cancer Discovery · 2012 · 320 citations

Cell Death, Cytoskeleton, Cell Cycle +24

The Immune Checkpoint Regulator PD-L1 Is Highly Expressed in Aggressive Primary Prostate Cancer

Heidrun Gevensleben, Dimo Dietrich, Carsten Golletz et al. · Clinical Cancer Research · 2015 · 230 citations